Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Reprint Policy Expands To Clinical Practice Guidelines, Medical Reference Texts

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA has revised, but not loosened, its 2009 final guidance on good reprint practices for distribution of journal articles on unapproved uses of approved drugs and devices.

You may also be interested in...



Rx Drug Promotion Studies Target Biosimilar Disclosures, Unapproved Uses, Multiple Indications

US FDA proposes studies to look at the impact of disclosure of a product’s secondary claims and biosimilar designation; disclosure about unapproved uses; and the impact of citing a drugs multiple indications in TV ads.

FDA’s New Criminal Investigations Chief Wants Global Reach

Office of Criminal Investigations Director George Karavetsos talks about the Park Doctrine and off-label enforcement in an interview.

FDA’s New Criminal Investigations Chief Wants Global Reach

Office of Criminal Investigations Director George Karavetsos talks about the Park Doctrine and off-label enforcement in interview with “The Pink Sheet.”

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL009864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel